Coya Therapeutics (COYA) Competitors $5.31 -0.25 (-4.50%) Closing price 04:00 PM EasternExtended Trading$5.32 +0.01 (+0.09%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. ADCT, CGEM, BNTC, DMAC, PRTC, MNPR, AUTL, RCKT, CGC, and IMRXShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include ADC Therapeutics (ADCT), Cullinan Therapeutics (CGEM), Benitec Biopharma (BNTC), DiaMedica Therapeutics (DMAC), PureTech Health (PRTC), Monopar Therapeutics (MNPR), Autolus Therapeutics (AUTL), Rocket Pharmaceuticals (RCKT), Canopy Growth (CGC), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Its Competitors ADC Therapeutics Cullinan Therapeutics Benitec Biopharma DiaMedica Therapeutics PureTech Health Monopar Therapeutics Autolus Therapeutics Rocket Pharmaceuticals Canopy Growth Immuneering Coya Therapeutics (NASDAQ:COYA) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Does the media favor COYA or ADCT? In the previous week, Coya Therapeutics had 5 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 0 mentions for ADC Therapeutics. Coya Therapeutics' average media sentiment score of 0.44 beat ADC Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Neutral ADC Therapeutics Neutral Is COYA or ADCT more profitable? Coya Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -220.00%. ADC Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -61.05% -53.61% ADC Therapeutics -220.00%N/A -53.73% Do analysts rate COYA or ADCT? Coya Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 210.73%. ADC Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 125.42%. Given Coya Therapeutics' higher probable upside, research analysts plainly believe Coya Therapeutics is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, COYA or ADCT? Coya Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M25.02-$14.88M-$1.24-4.28ADC Therapeutics$70.84M5.46-$157.85M-$1.57-2.19 Which has more risk & volatility, COYA or ADCT? Coya Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Do insiders & institutionals have more ownership in COYA or ADCT? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCoya Therapeutics beats ADC Therapeutics on 9 of the 14 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.99M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-4.2820.6375.7726.11Price / Sales25.02442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book2.249.6212.876.30Net Income-$14.88M-$52.73M$3.29B$271.03M7 Day Performance-7.49%0.64%-0.26%-0.15%1 Month Performance-18.31%6.31%3.84%6.41%1 Year Performance-12.23%18.97%68.35%28.81% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.6706 of 5 stars$5.31-4.5%$16.50+210.7%-6.7%$92.99M$3.55M-4.286News CoverageADCTADC Therapeutics2.0616 of 5 stars$3.31+3.4%$7.75+134.1%+16.6%$372.37M$77.25M-2.11310Positive NewsCGEMCullinan Therapeutics2.2827 of 5 stars$6.29-0.9%$27.67+339.9%-65.8%$371.58MN/A-1.9530BNTCBenitec Biopharma1.6976 of 5 stars$13.92+1.6%$24.80+78.2%+57.6%$365.40M$80K-9.2220Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionDMACDiaMedica Therapeutics2.0811 of 5 stars$6.97-0.6%$12.33+76.9%+70.0%$360.27MN/A-10.1020Positive NewsPRTCPureTech Health0.6839 of 5 stars$14.70-4.5%N/A-11.1%$355.30M$4.83M0.00100Positive NewsGap UpMNPRMonopar Therapeutics2.0186 of 5 stars$57.00+4.6%$71.75+25.9%+1,556.2%$351.69MN/A-17.1210News CoverageAnalyst ForecastGap UpAUTLAutolus Therapeutics3.9852 of 5 stars$1.32flat$9.12+590.9%-55.6%$351.31M$29.93M-1.57330Positive NewsAnalyst ForecastHigh Trading VolumeRCKTRocket Pharmaceuticals4.7998 of 5 stars$3.25+0.9%$16.73+414.9%-81.8%$350.68MN/A-1.29240Positive NewsGap DownCGCCanopy Growth1.0082 of 5 stars$1.45+4.3%N/A-69.1%$347.78M$274.92M-0.483,150Positive NewsGap DownIMRXImmuneering3.4882 of 5 stars$8.31+5.7%$13.75+65.5%+216.1%$345.45M$320K-4.4060Trending NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies ADC Therapeutics Competitors Cullinan Therapeutics Competitors Benitec Biopharma Competitors DiaMedica Therapeutics Competitors PureTech Health Competitors Monopar Therapeutics Competitors Autolus Therapeutics Competitors Rocket Pharmaceuticals Competitors Canopy Growth Competitors Immuneering Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
